Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowe…
Drug Manufacturers - Specialty & Generic
US, Boston [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Ironwood Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -1.3900 | -0.880 | 76 | 138 | -189 | -114 | -156 | -74 | -169 | -77 | 118 | 112 |
| 2016 | -1.0000 | -0.550 | 149 | 262 | -142 | -92 | -99 | -33 | -84 | -55 | 125 | 209 |
| 2017 | -0.5600 | -0.892 | 273 | 289 | -81 | -99 | -31 | -48 | -41 | -58 | 173 | 240 |
| 2018 | -0.7900 | -1.361 | 298 | 308 | -116 | -243 | -33 | -193 | -108 | -190 | 233 | 247 |
| 2019 | -1.8500 | 0.132 | 346 | 415 | -282 | 81 | -144 | 162 | -102 | 197 | 241 | 345 |
| 2020 | -0.0982 | 0.678 | 428 | 383 | -15 | 74 | 101 | 102 | 117 | 104 | 172 | 114 |
| 2021 | 0.6700 | 3.255 | 389 | 407 | 106 | 357 | 141 | 202 | 158 | 201 | 140 | 97 |
| 2022 | 3.2600 | 0.972 | 413 | 411 | 528 | 203 | 233 | 281 | 230 | 278 | 111 | 137 |
| 2023 | 1.1300 | -5.851 | 410 | 442 | 175 | -1,002 | 261 | 309 | 248 | 306 | 115 | 151 |
| 2024 | -6.4500 | 0.100 | 442 | 353 | -1,002 | 15 | -924 | 56 | -842 | 54 | 158 | 118 |
| 2025 | - | 0.255 | - | 346 | - | 36 | - | 55 | - | 53 | - | 115 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |